Drug Profile
Research programme: monoclonal antibody-based cancer therapeutics - Immatics N.V./MorphoSys
Latest Information Update: 07 Jul 2020
Price :
$50
*
At a glance
- Originator immatics biotechnologies GmbH; MorphoSys
- Developer Immatics N.V.; MorphoSys
- Class Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer